NCT00401804View on ClinicalTrials.gov

Bortezomib-Dexamethasone-Doxorubicin-Study

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2009

Conditions
Multiple MyelomaRenal Insuficiency
Interventions
DRUG

Dexamethasone, Bortezomib, Doxorubicin

Trial Locations (9)

1090

Medical University of Vienna, Dep. of Internal Medicine I, Vienna

Universitätsklinik für Innere Medizin I, Vienna

1160

Wilhelminenspital Vienna, 1st Med. Department - center for Oncology and Hematology, Vienna

4600

Klinikum Kreuzschwestern Wels GmbH, Wels

5020

Dep. of Internal Medicine I, Oncology, SALK - Gemeinnützige Salzburger Landeskliniken, Salzburg

8036

Klinischen Abteilung für Hämatologie, Medizinische Universitätsklinik Graz, Graz

62500

FN Brno Interni Hematoonkolog. klinika, Brno

Unknown

Landeskrankenhaus Feldkirch, Feldkirch

Landeskrankenhaus Leoben, Leoben

All Listed Sponsors
lead

Austrian Forum Against Cancer

OTHER

NCT00401804 - Bortezomib-Dexamethasone-Doxorubicin-Study | Biotech Hunter | Biotech Hunter